ASCERTAIN (Affordability and Sustainability improvements through new pricing, Cost- Effectiveness and ReimbursemenT models to Appraise INnovative health technologies) addresses the need of patients, physicians, payers, regulators, and manufacturers to improve the affordability and accessibility to innovative health technologies (including pharmaceuticals) in Europe.



ASCERTAIN is a project aimed at helping people get better access to new health technologies such as medicines, medical devices, and tests. The project is creating a tool that can be used by decision-makers to understand the cost and value of these new health technologies.

What is the ASCERTAIN policy support tool?

The tool will be accessible to everyone on the internet and will have information about the cost and value of these new health technologies. It will also consider the impact on the environment. The project will work with patients, industry, policy makers, and payers to make sure the tool is good quality and useful.

Why is the affordability of innovative health technologies a challenge?

It’s a challenge for many countries in the European Union to afford new health technologies because they are often expensive and not everyone has equal access to them. This tool will help decision-makers understand how much these technologies should cost and how much they can save the healthcare system.

What are the goals of ASCERTAIN?

The goal of ASCERTAIN is to make it easier for people to understand the cost and value of new health technologies. The tool will be open to everyone and will be able to be adapted to different countries’ needs. It will have information about the cost and value of these technologies and will encourage “greener” production.



A catalyst for collaborative advances in cancer immunotherapy

On 16th of February, Dr Frederick Thielen represented ASCERTAIN at the 6th European CAR T-cell Meeting. His journey began by attending the meeting of the T2EVOLVE consortium, an EU-funded initiative pioneering collaboration between leading scientists and industry in cancer immunotherapy. This ground-breaking alliance aims to...
Read more


Navigating Challenges in Health Economics and Outcomes Research

Last week, Carin Uyl-de Groot, Mirjana Huić, Nicolas Xander and Isabelle Durand-Zaleski presented ASCERTAIN in Copenhagen. Their session was entitled: "Horizon Europe Project Ascertain: Supporting a sustainable and transparent EU HTA regulatory framework, accessibility of innovative technologies and health equity".

In this session,...
Read more


Dear Readers, 

The affordability of newly approved innovative health technologies (IHTs) is challenging in many health systems. Health care payers and health care industry across the European Union (EU) have explored different ways of defining payment for new products. ASCERTAIN addresses the need of patients, physicians, payers, regulators,...
Read more

In Memoriam: Margreet Franken

From: iMTA NEWSLETTER September 2023

With deep sorrow we share the heartbreaking news of the loss of our dear colleague, Margreet Franken. Margreet started her professional career as a nurse, specialised in coronary and intensive care nursing. Over the years, she held various positions in hospitals located in Arnhem, Rotterdam, and Christchurch (New Zealand)....
Read more

ASCERTAIN Project at EHA2023: Improving Access to Innovative Health Technologies in Europe

Prof. Carin Uyl-de Groot Presents ASCERTAIN, Focusing on Affordable CAR-T Cell Therapies and Cancer Care in Eastern Europe

The European Hematology Association (EHA) is dedicated to advancing hematological care, research, and education on a global scale. Through collaborations with medical professionals, national hematology societies, patient groups, the medical industry, and media, EHA strives...
Read more

ASCERTAIN project takes off with great success in Rotterdam

ASCERTAIN — from project idea to Grant Agreement

Read the latest Spinverse article about ASCERTAIN

Prof. Dr. Carin Uyl-de Groot from Erasmus University Rotterdam spoke about taking upon the role of Project Coordinator in the consortium project that recently secured funding from Horizon Europe. Together with nine partners, Erasmus School of Health Policy & Management, has launched the ASCERTAIN project...
Read more



Webinar: Basics of medicines pricing in Europe

Myeloma Patients Europe (MPE) will hold the webinar “Basics of medicines pricing in Europe” on Thursday 7th March 2024 from 15:00 – 16:30 CET.

Through this webinar you will understand the basics of drug pricing (with a focus on high-cost branded medicines) and the processes and policies that influence it. The webinar will be given by Sabine Vogler, Director of the WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies and Head of Pharmacoeconomics Department, Austrian National Public Health Institute, who will give a 45-minute presentation followed by a 30-minute Q&A session. Registration is free of charge.

Feel free to forward the registration link to colleagues and other patient advocates who might be interested in attending the webinar. Should you be unable to attend the webinar, please feel free to send your questions in advance to gro.eporuepm@ofni and we will make sure they reach the speaker. A recording of the webinar will be available shortly after the session. Keep an eye out for our social media profiles! We look forward to your participation.

Click here to register.



Join partners from ASCERTAIN project the EAA SPRING CONVENTION 2024 in Rotterdam.

Stay tuned for more information!


5th PPRI Conference 2024: Ensuring access to affordable medicines through innovative policies

Equitable access to quality-assured, safe and affordable medicines, vaccines and medical devices is fundamental to a functioning health system. Over the last few decades, innovations in life sciences have saved millions of lives yet millions more worldwide still suffer from a lack of access to medicines that they would need for acute and/or chronic diseases. Countries face a range of obstacles including rising prices for new medicines putting the financial sustainability of healthcare systems at risk, shortages and stock-outs of essential medicines and irrational use of medicines (e.g. antibiotics) […] Click here for more information.


Please get in touch with us if you have any questions or comments! We will get back to you as soon as possible.

For research-related questions:

Carin Uyl-de Groot
Project Coordinator

Erasmus University Rotterdam
Phone: +31 10 4081583

For general project questions:

Marcel Langone Marques
Project Manager

Erasmus University Rotterdam
Phone: +31 10 4081583

For communications:

Lena Jessen
Project Manager

Phone: +49 40 226211490

Our Partners